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LETTERS TO THE EDITORRegarding “Limb-salvage angioplasty in vascular
surgery practice”
We read with great interest the article on infrainguinal angio-
plasty for limb salvage by Tefera et al.1 Although distal bypasses are
considered as the most durable revascularization procedures for
patients with chronic critical limb ischemia secondary to infrapop-
liteal occlusive disease,2 there is increasing evidence of usefulness of
endovascular techniques. We would like to make some necessary
comments regarding this study, which adds to the growing litera-
ture on infrapopliteal angioplasty.
1. There is frequently a multisegmental or multivessel in-
volvement (ie, two or three crural arteries) in these pa-
tients.3 Did the authors consider recanalization of one
patent vessel as a technical success, or was an attempt made
to open up more than one vessel in the leg?
2. Complications such as major dissection or plaque disrup-
tion with subsequent thrombosis may result in an acute
deterioration in the severity of ischemia, especially so if the
major collaterals are involved. As the “bail-out” option of
stent is not applicable to these vessels, what was the treat-
ment protocol for such events?
3. Was surgical revascularization needed on an emergent
basis? This would mandate a good surgical backup for
endovascular procedures.
4. We agree with the authors that ankle-brachial index mea-
surements may not be helpful in more than 50% of patients
during the follow-up period. What was their method of
evaluation in patients with non-compressible leg vessels?
We remain enthusiastic about this procedure and, like others,4,5
consider infrapopliteal angioplasty to be the initial choice for
management of critical limb ischemia. We are a group of vascular
surgeons who realized the magnitude of endovascular options
more than 14 years ago and use subintimal angioplasty especially in
diabetic patients with significant comorbidities. Long-term pa-
tency rates may not be as high or comparable with surgical revas-
cularization, but if relief of rest pain wound healing and limb
salvage can be achieved by a nonsurgical, minimally invasive op-
tion, the procedure has a good future.
Rajiv Parakh, FRCS
Sumit Kapadia, MS
Ajay Yadav, MS
Department of Vascular and Endovascular Surgery
Sir Ganga Ram Hospital
New Delhi, India
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Reply
We agree with Dr Parakh in that percutaneous infrainguinal
revascularization is an important adjunct and that there is growing
evidence about its usefulness in a selected group of patients. Short
of good prospective studies, however, some important questions
(such as durability) may not be easily answered. Dr Parakh raises
some important questions.
1. We attempted to revascularize more than one crural vessel.
Unfortunately, we could not make conclusive statements be-
cause some of our data were incomplete; however, recanalizing
one vessel was considered a technical success. The question
remains whether revascularizing more than one vessel can have
better clinical success.
2. We had only one case in which thrombosis with clinical deteri-
oration occurred, and this patient was treated with an overnight
thrombolysis. As a bailout very recently (since the publication
of this article), we have used small coronary stent.
3. We are a group of vascular surgeons and do not need any
backup. Overall, complications requiring emergency operation
are rare. In our series, no case needed emergency revasculariza-
tion.
4. All patients are followed up clinically for resolution of symp-
toms such as rest pain, healing of wounds, or toe amputation
sites. Superficial femoral artery lesions can be followed up by
duplex ultrasonography. We are currently evaluating tissue
oxygen tension on the dorsum of the foot to quantify improve-
ments in oxygenation.
Girma Tefera, MD
Department of Surgery
Section of Vascular Surgery
University of Wisconsin
Madison, Wis
doi:10.1016/j.jvs.2005.08.028
Regarding “Lifeline registry of endovascular
aneurysm repair: Long-term primary
outcome measures”
I read with interest the results of long-term follow-up of
patients in the Lifeline Registry of endovascular aneurysm repair
(EVAR; J Vasc Surg 2005;42:1-10) and take issue with the au-
thors’ conclusion that EVAR is an effective and durable treatment
for infrarenal aortic aneurysms. This conclusion is based on a low
risk of aneurysm rupture and aneurysm-related death and a low
surgical conversion rate. However, most EVARs were performed
in patients with small aneurysms (1040 patients had aneurysms
5.5 cm in diameter), and it is known that open surgery does not
confer a survival advantage for at least 8 years when such patients
are compared with those assigned to aneurysm surveillance.1 Al-
though the natural history of small aneurysms remains uncertain,
reports of rupture incidence for aneurysms smaller than 5 cm range
from 0% at 5 years to 1% per year.2,3 Unlike open surgery, in which
the diseased vessel is replaced by a prosthetic graft, EVAR allows
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in EVAR patients, particularly those with small aneurysms, does
not necessarily reflect graft durability or effectiveness. Reports of
loss of the survival advantage conferred by EVAR when compared
with open repair after 1 year of follow-up,4 as well as the present
study’s finding that preoperative aneurysm size was predictive of
rupture after EVAR, do not equate with graft durability. Indeed,
stent fractures have been reported in 71% of for-cause explanted
grafts and in 31% of incidentally explanted grafts.5
Although the need for secondary intervention in 18.28% of
EVAR patients reflects on the effectiveness of the grafts, as well as
on the skill required for their successful deployment, late secondary
intervention in 2.7% of EVAR patients must be assumed to relate
to stent graft failure over time, unless the authors state otherwise.
This is at least as relevant a measure of graft durability as freedom
from rupture. Eighteen aneurysm ruptures were reported in the
EVAR group, and 8 aneurysm-related deaths were reported be-
tween years 1 and 6. A total of 34% of the EVAR group died during
5 years of follow-up, and further information on causes of death
would be of interest. Classification of cause of death as verified,
probable, or indeterminate, as recommended by reporting stan-
dards for aortic EVAR,6 is not provided.
Brian J. Manning, MD
Department of Surgery
Cork University Hospital
Cork, Ireland
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Dr Manning takes issue with our conclusion that endovascular
aneurysm repair (EVAR) is an effective and durable treatment of
infrarenal aortic aneurysms because the conclusion is based on a
low aneurysm rupture and aneurysm-related death rate and a low
surgical conversion rate. However, prevention of aneurysm rup-
ture and death from rupture is precisely why aortic aneurysms are
treated. Therefore, the effectiveness and durability of EVAR in
achieving these objectives must be viewed as the primary outcome
measures. The Lifeline Registry data show that EVAR was effective
in preventing aneurysm rupture in 99% of patients over a 6-year
follow-up period. Similarly, EVAR was effective in preventing
aneurysm-related death in 98% of patients, with no diminution of
effectiveness over the 6-year follow-up period.1 Although avoiding“surgical conversion”—or open surgical repair—is not a primary
objective of aneurysm treatment per se, it is an objective of EVAR.
Thus, the low surgical conversion rate reported by the Lifeline
Registry must be viewed as evidence of the effectiveness and
durability of EVAR in achieving the objective of avoiding open
surgical repair. In this regard, it should be noted that the surveil-
lance strategy for small aneurysms to which Dr Manning refers2
was not entirely effective in preventing aneurysm rupture and
death, because 1% of small aneurysms ruptured each year despite
close surveillance and early treatment, if needed. Furthermore, the
mortality rate for rupture was very high (90%): 11% of all deaths in
the surveillance group were due to aneurysm rupture. Surveillance
also was not a durable strategy in the UK small aneurysm trial,
because 74% of patients in the surveillance group were treated with
open surgery over an 8-year follow-up period.2
With regard to reports of a loss of EVAR’s early survival
advantage over open surgery after 1 year, no information on graft
durability was provided.3 Indeed, the use of all-cause mortality as
the primary end point in these trials may obscure information
related to the long-term durability of each aneurysm treatment
strategy, because most deaths were due to non–aneurysm-related
causes. In the prospective, randomized EVAR-1 trial, the reduc-
tion in the aneurysm-related death rate after EVAR (4%) remained
lower than that after open surgery (7%) at 4 years (P  .04).4
Similarly, there was a persistent low aneurysm-related death rate
after EVAR in the Lifeline Registry (2% at 6 years). The threefold
reduction in perioperative mortality which was demonstrated in
the prospective randomized trials,3,4 along with the reduced mor-
bidity and more rapid recovery after EVAR, is a significant advan-
tage to the patient despite subsequent late death from unrelated
causes.
The Lifeline Registry report was focused on the primary
outcome measures of EVAR as a treatment strategy and not on the
specifics of individual device durability. As Dr Manning indicates,
adverse events and endograft device failures can occur after EVAR.
After 5 years, 22% of patients in the Lifeline Registry had under-
gone a secondary interventional procedure, and 5% had undergone
surgical conversion. Nonetheless, the long-term primary outcome
measures remained stable, with no suggestion of an increasing
aneurysm rupture or aneurysm-related death rate over time, and
open surgical repair had been avoided in 95% of patients. Thus,
EVAR can be viewed as an effective and durable treatment strategy,
within the 6-year time frame of the study, provided that patients
are monitored and secondary treatments are performed when
needed.
Christopher K. Zarins, MD, on behalf of the Lifeline Registry of
EVAR Publications Committee
REFERENCES
1. Lifeline Registry of EVAR Publications Committee. Lifeline registry of
endovascular aneurysm repair: long-term primary outcome measures. J
Vasc Surg 2005;42:1-10.
2. United Kingdom Small Aneurysm Trial Participants. Long-term out-
comes of immediate repair compared with surveillance of small abdomi-
nal aortic aneurysms. N Engl J Med 2002;346:1445-52.
3. Blankensteijn JD, de Jong SE, Prinssen M, van der Ham AC, Buth J, van
Sterkenburg SM, et al. Two-year outcomes after conventional or endo-
vascular repair of abdominal aortic aneurysms. N Engl J Med 2005;352:
2398-405.
4. EVAR Trial Participants. Endovascular aneurysm repair and outcome
in patients unfit for open repair of abdominal aortic aneurysm (EVAR
trial 2): randomised controlled trial. Lancet 2005;365:2187-92.doi:10.1016/j.jvs.2005.10.016
